227 filings
Page 5 of 12
8-K
h2ou9cjxxf
10 Feb 20
Departure of Directors or Certain Officers
6:46am
8-K
1o9528
23 Dec 19
Other Events
4:17pm
8-K
ae66ero5gad5
25 Nov 19
Entry into a Material Definitive Agreement
4:06pm
8-K
1pkz zhwjwb
13 Nov 19
Brickell Bio Announces Third Quarter 2019
4:10pm
8-K
xs10xnq1
30 Oct 19
Brickell Biotech Provides Update on Bodor Labs Complaint and Funding Agreement with NovaQuest
4:44pm
8-K
qftamyio1
24 Oct 19
Other Events
8:50am
8-K
k738xc1jtf7u nov
9 Oct 19
Entry into a Material Definitive Agreement
7:01am
8-K
bzk bal511
3 Sep 19
Brickell Biotech Completes Merger with Vical
7:02am
8-K
z7j re3nzg033jn2
30 Aug 19
Departure of Directors or Certain Officers
11:42am
8-K
tyklv vkxei
21 Aug 19
Entry into a Material Definitive Agreement
5:08pm
8-K
kbn9050vxqc784dnxpo
18 Jul 19
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
6:30am
8-K
9kb9f6vm gpd0wpo6
3 Jun 19
Vical and Brickell Announce Merger Agreement
5:05pm
8-K
ktlkz clvqje71cp76e
24 May 19
Departure of Directors or Certain Officers
4:05pm
8-K
67261g2ofe5jke5zxi90
20 Feb 19
Vical to Discontinue Clinical Development of VL-2397 as it Considers Near Term Strategic Alternatives
12:00am
8-K
nwzhadp
29 Nov 18
Amendments to Articles of Incorporation or Bylaws
4:05pm
8-K
9fk19cozyfybiq y7
29 Oct 18
Vical Reports Third Quarter 2018 Financial and Operational Results
6:30am
8-K
riipwex4 0v39
7 Aug 18
Vical Reports Second Quarter 2018 Financial and Operational Results
6:35am
8-K
n9da5dydb2mh
11 Jun 18
Vical Reports Phase 2 Trial of HSV-2 Therapeutic Vaccine Did Not Meet Primary Endpoint
12:00am
8-K
hp6q0
7 Jun 18
Departure of Directors or Certain Officers
7:00am
8-K
07gb7n1eq
3 May 18
Vical Reports First Quarter 2018 Financial and Operational Results
12:00am